Latest On Interpace Biosciences, Inc (IDXG):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-13 00:43 EST | News | Interpace Biosciences GAAP EPS of $0.10, revenue of $9.8M | N/A |  |
| 2023-03-28 07:32 EST | News | Interpace Biosciences GAAP EPS of -$0.33, revenue of $8.33M | N/A | |
| 2022-11-15 03:29 EST | News | Interpace Biosciences GAAP EPS of $3.35, revenue of $8.2M | N/A | |
| 2022-09-01 06:44 EST | News | Interpace Biosciences completes sale of pharma services business to Flagship Biosciences | N/A | |
| 2022-05-17 07:57 EST | News | Interpace Biosciences GAAP EPS of -$0.53, revenue of $10.38M | N/A | |
| 2022-04-01 07:39 EST | News | Interpace Biosciences GAAP EPS of -$0.89, revenue of $10.86M | N/A | |
| 2022-01-12 23:53 EST | News | Interpace Biosciences begins $30M rights offering | N/A | |
| 2022-01-03 21:59 EST | News | Interpace Biosciences to undertake $30M rights offering | N/A | |
| 2021-11-17 19:22 EST | News | Interpace downgraded to Neutral at H.C. Wainwright after Q3 financials | N/A | |
| 2021-11-11 07:31 EST | News | Interpace Biosciences EPS misses by $0.23, misses on revenue | N/A | |
| 2021-10-22 13:10 EST | News | Interpace falls despite US patent for distinguishing benign from malignant thyroid tissue | N/A | |
| 2021-10-15 15:47 EST | News | Interpace Biosciences announces new $7.5M credit facility | N/A | |
| 2021-08-11 02:35 EST | News | Interpace Biosciences EPS misses by $0.35, beats on revenue | N/A | |
| 2021-04-19 11:35 EST | News | Interpace Biosciences pushes FY 2021 revenue guidance above estimates | N/A | |
| 2021-03-31 22:41 EST | News | Interpace Biosciences EPS misses by $0.69, beats on revenue | N/A | |
| 2021-03-18 00:23 EST | News | Interpace Biosciences to divest new haven CLIA lab to Diamir | N/A | |
| 2021-02-26 03:55 EST | Analyst Rating | The Analyst Target Price has increased from $8.43 to $9. | Buy | |
| 2021-02-17 22:41 EST | News | Interpace Bio drops after news of delisting from Nasdaq | N/A | |
| 2021-02-15 11:47 EST | Analyst Rating | The Analyst Target Price has decreased from $9.2 to $8.43. | Neutral | |
| 2021-02-05 09:41 EST | News | Interspace Biosciences trades high, appoints new finance chief | N/A | |
| 2021-02-03 12:00 EST | Analyst Rating | The Analyst Target Price has decreased from $10.2 to $9.2. | Neutral | |
| 2021-02-01 14:59 EST | News | Interpace signs licensing agreement for monoclonal antibody platform Das-1 | N/A | |
| 2021-01-26 11:54 EST | Analyst Rating | The Analyst Target Price has increased from $10.13 to $10.2. | Buy | |
| 2021-01-22 00:01 EST | Financials | Company financials have been released. | Neutral | |
| 2021-01-21 11:59 EST | Earnings Estimate | An EPS average of -$0.72 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2021-01-20 19:15 EST | News | Interpace Biosciences EPS misses by $0.33, beats on revenue | N/A | |
| 2021-01-15 11:55 EST | Analyst Rating | The Analyst Target Price has decreased from $12.13 to $10.13. | Neutral | |
| 2020-11-26 20:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 12:34 EST | Analyst Rating | The Analyst Target Price has decreased from $12.5 to $12.13. | Neutral | |
| 2020-11-18 16:29 EST | News | Interpace Biosciences delays 10-Q filing | N/A | |
| 2020-11-07 16:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 23:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-30 13:31 EST | Analyst Rating | The Analyst Target Price has decreased from $13.45 to $12.5. | Neutral | |
| 2020-10-26 19:18 EST | News | Interpace Biosciences up 12% on validation of thyroid tests | N/A | |
| 2020-10-20 22:23 EST | News | Interpace Biosciences EPS misses by $0.32, misses on revenue | N/A | |
| 2020-10-14 15:41 EST | News | Interpace Bio prevails in fallacious employee complaints; shares +67% | N/A | |
| 2020-09-26 13:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 05:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-20 20:18 EST | News | Interpace receives deficiency notice from Nasdaq over delayed filing | N/A | |
| 2020-08-18 10:58 EST | News | Interpace Biosciences down 26% on potential compliance issues | N/A | |
| 2020-08-14 09:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 16:23 EST | Insider Trade | James Early has directly acquired 5,000 shares and currently holds 7,125 shares. | Buy | |
| 2020-07-31 01:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 17:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 09:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-07 08:50 EST | Earnings Estimate | An EPS average of -$0.97 is estimated for the quarter ending on September 30, 2020. | Buy | |
| 2020-07-07 08:50 EST | Analyst Rating | The Analyst Target Price has decreased from $13.64 to $13.45. | Neutral | |
| 2020-06-27 08:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-26 19:26 EST | News | Interpace Biosciences EPS misses by $1.07, beats on revenue | N/A | |
| 2020-06-26 19:25 EST | News | Interpace Biosciences, Inc. (IDXG) CEO Jack Stover on Q1 2020 Results - Earnings Call Transcript | N/A | |
About Interpace Biosciences, Inc (IDXG):
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
General
- Name Interpace Biosciences, Inc
- Symbol IDXG
- Type Common Stock
- Exchange OTCQX
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDiagnostics & Research
- Full Time Employees 176
- Last Split Factor1:10
- Last Split Date2020-01-15
- Fiscal Year EndDecember
- IPO Date1998-05-20
- Gic SectorHealth Care
- Gic GroupHealth Care Equipment & Services
- Gic IndustryHealth Care Providers & Services
- Gic SubIndustryHealth Care Services
- Web URLhttp://www.wearepdi.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 0.44
- Price/Book (Most Recent Quarter) 10.04
- Enterprise Value Revenue 2.18
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.94
- Profit Margin -108%
- Operating Margin -108%
- Return on Assets -29%
- Return on Equity -93%
- Revenue 26.83 million
- Earnings Per Share -$0.49
- Revenue Per Share $6.75
- Gross Profit 8.19 million
- Quarterly Earnings Growth 6.8%
View More
Highlights
- Market Capitalization 21.41 million
- EBITDA -8792000
- PE Ratio -0.19
- Analyst Target Price $9
- Book Value Per Share $0.42
View More
Share Statistics
- Shares Outstanding 4.06 million
- Shares Float 3.34 million
- % Held by Insiders 751%
- % Held by Institutions 17.14%
- Shares Short 47355
- Shares Short Prior Month 29806
- Short Ratio 0.19
- Short % of Float 1%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 0.91
- 52 Week High $8.32
- 52 Week Low $2.57
- 50 Day Moving Average 4.61
- 200 Day Moving Average 3.69
View More
Dividends
- Dividend Date 2020-01-15
- ExDividend Date N/A
- Dividend Yield 0%
View More
Interpace Biosciences, Inc (IDXG) Dividend Calendar:
IDXG's last dividend payment was made to shareholders on January 15, 2020.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Interpace Biosciences, Inc (IDXG) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-01-20 | -$1.54 | -$1.20 | -28.6% | |
| 2020-09-30 | 2020-10-19 | $N/A | -$1.36 | -$1.48 | 7.98% |
| 2020-06-30 | 2020-06-30 | $5.45 million | -$1.36 | -$1.48 | 8.11% |
| 2020-03-31 | 2020-06-25 | $N/A | -$2.32 | -$1.24 | -87.1% |
| 2019-12-31 | 2019-12-31 | $N/A | -$2.95 | -$0.74 | -298.65% |
| 2019-09-30 | 2019-11-13 | $7.73 million | -$1.90 | -$1.92 | 1.04% |
| 2019-06-30 | 2019-08-13 | $6.27 million | -$1.40 | -$0.68 | -107.41% |
| 2019-03-31 | 2019-05-13 | $6.01 million | -$1.00 | -$0.60 | -66.67% |
| 2018-12-31 | 2019-03-19 | $5.83 million | -$1.40 | -$0.93 | -51.35% |
| 2018-09-30 | 2018-11-13 | $5.75 million | -$1.10 | -$0.80 | -37.5% |
| 2018-06-30 | 2018-08-09 | $5.5 million | -$0.70 | -$0.97 | 27.59% |
| 2018-03-31 | 2018-05-15 | $4.81 million | -$1.10 | -$0.80 | -37.5% |
| 2017-12-31 | 2018-03-15 | $4.37 million | -$1.90 | -$1.10 | -72.73% |
| 2017-09-30 | 2017-11-13 | $4.2 million | -$1.50 | -$2.60 | 42.31% |
| 2017-06-30 | 2017-08-10 | $3.86 million | -$3.80 | ||
| 2017-03-31 | 2017-05-12 | $3.47 million | $0.55 | ||
| 2016-12-31 | 2017-03-29 | $3.12 million | $3.24 | ||
| 2016-09-30 | 2016-11-18 | $3.32 million | -$4.13 | ||
| 2016-06-30 | 2016-08-16 | $3.61 million | -$1.29 | ||
| 2016-03-31 | 2016-05-12 | $3.04 million | -$2.69 | ||
| 2015-09-30 | 2015-11-12 | $36.63 million | -$2.50 | -$4.00 | 37.5% |
| 2015-06-30 | 2015-08-13 | $36.34 million | -$3.90 | -$0.45 | -766.67% |
| 2015-03-31 | 2015-05-12 | $38.32 million | -$20.00 | -$48.00 | 58.33% |
| 2014-12-31 | 2015-03-03 | $26.33 million | -$32.00 | -$49.50 | 35.35% |
| 2014-09-30 | 2014-11-03 | $29.25 million | -$29.00 | -$18.50 | -56.76% |
| 2014-06-30 | 2014-08-13 | $31.58 million | -$18.00 | -$11.50 | -56.52% |
| 2014-03-31 | 2014-05-07 | $32.78 million | -$11.00 | -$14.33 | 23.24% |
| 2013-12-31 | 2014-02-27 | $36.41 million | -$25.00 | -$11.33 | -120.65% |
| 2013-09-30 | 2013-11-12 | $34.26 million | -$15.00 | -$19.67 | 23.74% |
| 2013-06-30 | 2013-08-05 | $37.25 million | -$6.00 | -$11.00 | 45.45% |
| 2013-03-31 | 2013-05-13 | $42.92 million | $15.00 | -$11.00 | 236.36% |
| 2012-12-31 | 2013-03-06 | $35.63 million | $3.00 | -$6.50 | 146.15% |
| 2012-09-30 | 2012-11-05 | $31.78 million | -$6.00 | -$4.00 | -50% |
| 2012-06-30 | 2012-08-13 | $27.81 million | -$3.00 | -$6.50 | 53.85% |
| 2012-03-31 | 2012-05-14 | $31.68 million | -$2.00 | $2.00 | -200% |
| 2011-12-31 | 2012-03-07 | $38.28 million | $7.00 | -$3.50 | 300% |
| 2011-09-30 | 2011-11-09 | $36.07 million | -$1.00 | -$6.00 | 83.33% |
| 2011-06-30 | 2011-08-08 | $38.64 million | -$6.00 | -$13.00 | 53.85% |
| 2011-03-31 | 2011-05-03 | $44.3 million | -$4.00 | -$9.00 | 55.56% |
| 2010-12-31 | 2011-03-21 | $44.7 million | $3.00 | $2.00 | 50% |
| 2010-09-30 | 2010-11-03 | $35.97 million | $3.00 | -$11.00 | 127.27% |
| 2010-06-30 | 2010-08-04 | $32.85 million | -$2.00 | -$20.00 | 90% |
| 2010-03-31 | 2010-05-06 | $31.13 million | -$12.00 | -$9.00 | -33.33% |
| 2009-12-31 | 2010-03-04 | $23.07 million | -$10.00 | -$18.00 | 44.44% |
| 2009-09-30 | 2009-11-05 | $19.64 million | -$19.00 | -$35.00 | 45.71% |
| 2009-06-30 | 2009-08-05 | $14.14 million | -$39.00 | -$40.00 | 2.5% |
| 2009-03-31 | 2009-05-07 | $23.53 million | -$4.02 | ||
| 2008-12-31 | 2009-03-11 | $25.4 million | -$120.00 | -$70.00 | -71.43% |
| 2008-09-30 | 2008-11-06 | $24.5 million | -$64.00 | -$69.00 | 7.25% |
| 2008-06-30 | 2008-08-06 | $30.4 million | -$53.00 | -$50.00 | -6% |
| 2008-03-31 | 2008-05-08 | $32.23 million | -$8.00 | -$19.00 | 57.89% |
| 2007-12-31 | 2008-03-12 | $32.58 million | -$11.00 | -$29.00 | 62.07% |
| 2007-09-30 | 2007-11-08 | $23.97 million | -$29.00 | -$27.50 | -5.45% |
| 2007-06-30 | 2007-08-08 | $27.78 million | -$18.00 | -$31.50 | 42.86% |
| 2007-03-31 | 2007-05-09 | $32.8 million | -$14.00 | -$35.50 | 60.56% |
| 2006-12-31 | 2007-03-14 | $55.83 million | $1.00 | $2.33 | -57.08% |
| 2006-09-30 | 2006-11-07 | $51.32 million | $3.00 | $3.50 | -14.29% |
| 2006-06-30 | 2006-08-01 | $54.95 million | $5.00 | $12.00 | -58.33% |
| 2006-03-31 | 2006-05-01 | $77.14 million | $40.00 | $2.00 | 1900% |
| 2005-12-31 | 2006-03-01 | $78.34 million | -$143.00 | -$1.50 | -9433.33% |
| 2005-09-30 | 2005-11-03 | $72.85 million | -$3.00 | $1.50 | -300% |
| 2005-06-30 | 2005-08-08 | $76.06 million | $9.00 | $9.00 | 0% |
| 2005-03-31 | 2005-05-10 | $77.95 million | $13.00 | $24.00 | -45.83% |
| 2004-12-31 | 2005-03-09 | $87.81 million | $31.00 | $34.00 | -8.82% |
| 2004-09-30 | 2004-11-03 | $92.52 million | $37.00 | $32.50 | 13.85% |
| 2004-06-30 | 2004-08-09 | $91.46 million | $34.00 | $30.00 | 13.33% |
| 2004-03-31 | 2004-05-03 | $92.65 million | $40.00 | $33.50 | 19.4% |
| 2003-12-31 | 2004-03-03 | $99.22 million | $31.00 | $37.50 | -17.33% |
| 2003-09-30 | 2003-11-05 | $94.55 million | $29.00 | $20.00 | 45% |
| 2003-06-30 | 2003-08-05 | $77.62 million | $20.00 | $1.00 | 1900% |
| 2003-03-31 | 2003-05-07 | $73.13 million | $14.00 | $8.00 | 75% |
| 2002-12-31 | 2003-02-14 | $79.03 million | $38.00 | $6.80 | 458.82% |
| 2002-09-30 | 2002-11-13 | $64.57 million | -$18.00 | -$47.67 | 62.24% |
| 2002-06-30 | 2002-08-13 | $66.53 million | -$66.00 | -$20.17 | -227.22% |
| 2002-03-31 | 2002-05-13 | $73.88 million | -$16.00 | -$4.75 | -236.84% |
| 2001-12-31 | 2002-02-19 | $263.9 million | $59.00 | -$23.00 | 356.52% |
| 2001-09-30 | 2001-11-12 | $115.67 million | -$20.00 | -$49.00 | 59.18% |
| 2001-06-30 | 2001-08-13 | $143.94 million | $31.00 | $24.33 | 27.41% |
| 2001-03-31 | 2001-05-04 | $173.07 million | $77.00 | $70.22 | 9.66% |
| 2000-12-31 | 2001-02-15 | $185.43 million | $77.00 | $72.50 | 6.21% |
| 2000-09-30 | 2000-11-02 | $84.37 million | $41.00 | $34.57 | 18.6% |
| 2000-06-30 | 2000-07-31 | $75.79 million | $35.00 | $30.50 | 14.75% |
| 2000-03-31 | 2000-04-25 | $71.29 million | $43.00 | $29.40 | 46.26% |
| 1999-12-31 | 2000-02-02 | $24.00 | $21.33 | 12.52% | |
| 1999-09-30 | 1999-11-01 | $22.00 | $19.60 | 12.24% | |
| 1999-06-30 | 1999-07-29 | $24.00 | $22.00 | 9.09% | |
| 1999-03-31 | 1999-04-21 | $25.00 | $20.50 | 21.95% | |
| 1998-12-31 | 1999-02-09 | $14.00 | $10.00 | 40% | |
| 1998-09-30 | 1998-11-02 | $13.00 | $9.50 | 36.84% | |
| 1998-06-30 | 1998-08-05 | $11.00 | $8.00 | 37.5% |
Interpace Biosciences, Inc (IDXG) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | 550000 | N/A | N/A | 857000 |
| Income Before Tax | N/A | -5.42 million | N/A | N/A | -7.3 million |
| Selling General Administrative | N/A | 5.7 million | N/A | N/A | 7.25 million |
| Gross Profit | N/A | 1.6 million | N/A | N/A | 2.89 million |
| Ebit | N/A | -3.95 million | N/A | N/A | -6.21 million |
| Operating Income | N/A | -4.66 million | N/A | N/A | -6.21 million |
| Income Tax Expense | 14000 | 13000 | 15000 | -47000 | 9000 |
| Total Revenue | N/A | 5.45 million | N/A | N/A | 7.73 million |
| Cost of Revenue | N/A | 3.85 million | N/A | N/A | 4.84 million |
| Total Other Income Expense Net | N/A | -593000 | N/A | N/A | -1.08 million |
| Net Income From Continuing Operations | N/A | -5.43 million | N/A | N/A | -7.3 million |
| Net Income Applicable to Common Shares | -6.23 million | -5.5 million | -9.3 million | -10.65 million | -7.36 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | -913000 | N/A | N/A | N/A | N/A |
| Change to Liabilities | -1.11 million | N/A | -69000 | -530000 | 437000 |
| Total Cash Flow from Investing Activities | -913000 | N/A | -26000 | -13.89 million | -36000 |
| Net Borrowings | 2.2 million | N/A | -6.77 million | N/A | N/A |
| Total Cash Flow from Financial Activities | 2.2 million | N/A | N/A | 16.81 million | -53000 |
| Change to Operating Activities | 2.64 million | N/A | -1.51 million | -875000 | 326000 |
| Change in Cash | 1.74 million | N/A | N/A | -1.85 million | -4.91 million |
| Total Cash from Operating Activities | 449000 | -7.12 million | -6.4 million | -4.77 million | -4.83 million |
| Depreciation | 1.31 million | N/A | N/A | -1.75 million | 876000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | -13.92 million | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | 2.56 million | N/A | N/A | 3.98 million | -2.24 million |
| Other Cash Flow from Financing Activities | N/A | 18.17 million | N/A | 22.77 million | N/A |
| Change to Net Income | 544000 | -859000 | 3.61 million | 1.76 million | 1000000 |
| Capital Expenditures | N/A | N/A | N/A | -48000 | 36000 |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 37.92 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 23.6 million |
| Other Current Liabilities | 766000 | 4.57 million | N/A | N/A | 17.3 million |
| Total Assets | N/A | N/A | N/A | N/A | 74.67 million |
| Common Stock | 402000 | 402000 | 6.84 million | 393000 | 23.6 million |
| Other Current Assets | 3.86 million | 167000 | N/A | N/A | 18.22 million |
| Retained Earnings | -203.97 million | -179.92 million | N/A | -168.16 million | N/A |
| Other Liabilities | 6.62 million | 6.71 million | 55.95 million | 6.96 million | 20.62 million |
| Other Assets | 42000 | 42000 | 50.37 million | 42000 | 54.09 million |
| Cash | N/A | N/A | N/A | N/A | 2.36 million |
| Total Current Liabilities | 15.6 million | 16.1 million | N/A | N/A | 17.3 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 12.09 million | 12.42 million | N/A | 10.71 million | N/A |
| Total Current Assets | 17.63 million | 26.1 million | N/A | N/A | 20.58 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -42.74 million | -38.18 million | 6.84 million | -28.91 million | 23.6 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | 2.33 million | N/A | N/A | N/A |
| Accounts Payable | 3.39 million | 3.35 million | N/A | N/A | N/A |
Interpace Biosciences, Inc (IDXG) Chart:
Interpace Biosciences, Inc (IDXG) News:
Below you will find a list of latest news for Interpace Biosciences, Inc (IDXG) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Interpace Biosciences, Inc (IDXG) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Interpace Biosciences, Inc (IDXG) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315220011860/0001493152-20-011860-index.htm |
| 2018-10-16 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1054102/000000000018032467/0000000000-18-032467-index.htm |
| 2019-07-25 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924319020365/0000899243-19-020365-index.htm |
| 2019-07-25 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924319020367/0000899243-19-020367-index.htm |
| 2019-10-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924319025566/0000899243-19-025566-index.htm |
| 2019-10-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924319025567/0000899243-19-025567-index.htm |
| 2019-10-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924319025761/0000899243-19-025761-index.htm |
| 2019-10-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924319025773/0000899243-19-025773-index.htm |
| 2019-10-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924319025994/0000899243-19-025994-index.htm |
| 2019-10-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924319025995/0000899243-19-025995-index.htm |
| 2020-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924320001367/0000899243-20-001367-index.htm |
| 2020-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924320001370/0000899243-20-001370-index.htm |
| 2020-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000089924320001371/0000899243-20-001371-index.htm |
| 2018-01-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1054102/000090266418000160/0000902664-18-000160-index.htm |
| 2020-04-17 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1054102/000093583620000269/0000935836-20-000269-index.htm |
| 2020-09-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1054102/000093583620000512/0000935836-20-000512-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248218000490/0001192482-18-000490-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248218000491/0001192482-18-000491-index.htm |
| 2018-12-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248218000492/0001192482-18-000492-index.htm |
| 2019-03-08 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000122/0001192482-19-000122-index.htm |
| 2019-03-08 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000123/0001192482-19-000123-index.htm |
| 2019-03-08 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000124/0001192482-19-000124-index.htm |
| 2019-03-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000146/0001192482-19-000146-index.htm |
| 2019-03-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000147/0001192482-19-000147-index.htm |
| 2019-03-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000148/0001192482-19-000148-index.htm |
| 2019-03-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000149/0001192482-19-000149-index.htm |
| 2020-01-23 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000053/0001192482-20-000053-index.htm |
| 2020-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000058/0001192482-20-000058-index.htm |
| 2020-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000059/0001192482-20-000059-index.htm |
| 2020-01-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000060/0001192482-20-000060-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000075/0001192482-20-000075-index.htm |
| 2020-01-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000076/0001192482-20-000076-index.htm |
| 2020-02-04 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000096/0001192482-20-000096-index.htm |
| 2020-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000097/0001192482-20-000097-index.htm |
| 2020-02-04 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000098/0001192482-20-000098-index.htm |
| 2020-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000099/0001192482-20-000099-index.htm |
| 2019-07-25 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1054102/000119312519202514/0001193125-19-202514-index.htm |
| 2020-01-17 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1054102/000119312520010039/0001193125-20-010039-index.htm |
| 2020-04-23 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1054102/000119312520115197/0001193125-20-115197-index.htm |
| 2017-09-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315217010977/0001493152-17-010977-index.htm |
| 2017-09-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315217010978/0001493152-17-010978-index.htm |
| 2017-09-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315217010979/0001493152-17-010979-index.htm |
| 2017-10-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315217011532/0001493152-17-011532-index.htm |
| 2017-10-16 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315217011674/0001493152-17-011674-index.htm |
| 2017-11-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315217012822/0001493152-17-012822-index.htm |
| 2017-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315217012837/0001493152-17-012837-index.htm |
| 2018-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003186/0001493152-18-003186-index.htm |
| 2018-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003187/0001493152-18-003187-index.htm |
| 2018-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003190/0001493152-18-003190-index.htm |
| 2018-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003191/0001493152-18-003191-index.htm |
| 2018-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003194/0001493152-18-003194-index.htm |
| 2018-03-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003195/0001493152-18-003195-index.htm |
| 2018-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003293/0001493152-18-003293-index.htm |
| 2018-03-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003418/0001493152-18-003418-index.htm |
| 2018-03-23 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003786/0001493152-18-003786-index.htm |
| 2018-04-11 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315218005032/0001493152-18-005032-index.htm |
| 2018-04-30 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1054102/000149315218006003/0001493152-18-006003-index.htm |
| 2018-04-30 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1054102/000149315218006007/0001493152-18-006007-index.htm |
| 2018-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315218006330/0001493152-18-006330-index.htm |
| 2018-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315218006899/0001493152-18-006899-index.htm |
| 2018-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315218007054/0001493152-18-007054-index.htm |
| 2018-06-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315218008637/0001493152-18-008637-index.htm |
| 2018-07-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315218010696/0001493152-18-010696-index.htm |
| 2018-08-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315218011281/0001493152-18-011281-index.htm |
| 2018-08-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315218011292/0001493152-18-011292-index.htm |
| 2018-10-05 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1054102/000149315218014198/0001493152-18-014198-index.htm |
| 2018-10-17 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1054102/000149315218014576/0001493152-18-014576-index.htm |
| 2018-11-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315218015784/0001493152-18-015784-index.htm |
| 2018-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315218016132/0001493152-18-016132-index.htm |
| 2018-12-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315218017345/0001493152-18-017345-index.htm |
| 2019-01-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315219000930/0001493152-19-000930-index.htm |
| 2019-01-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315219001046/0001493152-19-001046-index.htm |
| 2019-01-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219001054/0001493152-19-001054-index.htm |
| 2019-02-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219002728/0001493152-19-002728-index.htm |
| 2019-03-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219003589/0001493152-19-003589-index.htm |
| 2019-03-21 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1054102/000149315219003733/0001493152-19-003733-index.htm |
| 2019-04-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219005628/0001493152-19-005628-index.htm |
| 2019-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219006949/0001493152-19-006949-index.htm |
| 2019-05-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315219007073/0001493152-19-007073-index.htm |
| 2019-07-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219010885/0001493152-19-010885-index.htm |
| 2019-07-29 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315219011227/0001493152-19-011227-index.htm |
| 2019-08-05 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1054102/000149315219011574/0001493152-19-011574-index.htm |
| 2019-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219011576/0001493152-19-011576-index.htm |
| 2019-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219012123/0001493152-19-012123-index.htm |
| 2019-08-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315219012225/0001493152-19-012225-index.htm |
| 2019-08-14 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219012255/0001493152-19-012255-index.htm |
| 2019-08-22 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1054102/000149315219013273/0001493152-19-013273-index.htm |
| 2019-09-20 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219014326/0001493152-19-014326-index.htm |
| 2019-09-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219014329/0001493152-19-014329-index.htm |
| 2019-09-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315219014377/0001493152-19-014377-index.htm |
| 2019-09-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219014380/0001493152-19-014380-index.htm |
| 2019-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219015530/0001493152-19-015530-index.htm |
| 2019-10-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219015610/0001493152-19-015610-index.htm |
| 2019-10-22 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments | https://www.sec.gov/Archives/edgar/data/1054102/000149315219015774/0001493152-19-015774-index.htm |
| 2019-10-22 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1054102/000149315219015776/0001493152-19-015776-index.htm |
| 2019-11-01 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1054102/000149315219016331/0001493152-19-016331-index.htm |
| 2019-11-14 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1054102/000149315219017260/0001493152-19-017260-index.htm |
| 2019-11-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219017468/0001493152-19-017468-index.htm |
| 2019-11-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315219017510/0001493152-19-017510-index.htm |
| 2019-12-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315219019362/0001493152-19-019362-index.htm |
| 2020-01-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220000548/0001493152-20-000548-index.htm |
| 2020-01-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220000562/0001493152-20-000562-index.htm |
| 2020-01-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220000711/0001493152-20-000711-index.htm |
| 2020-01-23 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1054102/000149315220000992/0001493152-20-000992-index.htm |
| 2020-01-23 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220000994/0001493152-20-000994-index.htm |
| 2020-01-27 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220001162/0001493152-20-001162-index.htm |
| 2020-01-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220001236/0001493152-20-001236-index.htm |
| 2020-01-28 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220001237/0001493152-20-001237-index.htm |
| 2020-01-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220001450/0001493152-20-001450-index.htm |
| 2020-02-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220001532/0001493152-20-001532-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220001534/0001493152-20-001534-index.htm |
| 2020-02-10 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220001864/0001493152-20-001864-index.htm |
| 2020-02-10 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220001865/0001493152-20-001865-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220005074/0001493152-20-005074-index.htm |
| 2020-04-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220005921/0001493152-20-005921-index.htm |
| 2020-04-22 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1054102/000149315220006897/0001493152-20-006897-index.htm |
| 2020-04-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220006925/0001493152-20-006925-index.htm |
| 2020-04-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220007158/0001493152-20-007158-index.htm |
| 2020-04-30 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1054102/000149315220007400/0001493152-20-007400-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220007758/0001493152-20-007758-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220008888/0001493152-20-008888-index.htm |
| 2020-05-20 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1054102/000149315220009451/0001493152-20-009451-index.htm |
| 2020-05-29 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1054102/000149315220010133/0001493152-20-010133-index.htm |
| 2020-06-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220010861/0001493152-20-010861-index.htm |
| 2020-06-10 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1054102/000149315220010891/0001493152-20-010891-index.htm |
| 2020-06-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220011832/0001493152-20-011832-index.htm |
| 2020-06-26 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315220011860/0001493152-20-011860-index.htm |
| 2020-07-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220013113/0001493152-20-013113-index.htm |
| 2020-07-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220013114/0001493152-20-013114-index.htm |
| 2020-07-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220013115/0001493152-20-013115-index.htm |
| 2020-07-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220013137/0001493152-20-013137-index.htm |
| 2020-07-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220013262/0001493152-20-013262-index.htm |
| 2020-07-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1054102/000149315220014326/0001493152-20-014326-index.htm |
| 2020-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220015960/0001493152-20-015960-index.htm |
| 2020-08-14 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | https://www.sec.gov/Archives/edgar/data/1054102/000149315220015963/0001493152-20-015963-index.htm |
| 2020-08-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220016383/0001493152-20-016383-index.htm |
| 2020-10-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220019408/0001493152-20-019408-index.htm |
| 2020-10-19 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1054102/000149315220019627/0001493152-20-019627-index.htm |
| 2020-10-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220019643/0001493152-20-019643-index.htm |
| 2020-10-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1054102/000149315220019875/0001493152-20-019875-index.htm |
| 2018-01-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1054102/000153561018000027/0001535610-18-000027-index.htm |
| 2020-07-24 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1054102/000178397620000013/0001783976-20-000013-index.htm |
| 2020-08-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1054102/000178397620000015/0001783976-20-000015-index.htm |
| 2018-10-19 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1054102/999999999518002672/9999999995-18-002672-index.htm |
Interpace Biosciences, Inc (IDXG) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Interpace Biosciences, Inc (IDXG). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 751%Institutional Ownership: 1714%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-03-07 | James Early | Chief Financial Officer | Buy | 14,000.00 | 14,000.00 | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003186/0001493152-18-003186-index.htm | ||
| 2018-03-07 | JOSEPH D KEEGAN | Director | Buy | 4,800.00 | 17,569.00 | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003191/0001493152-18-003191-index.htm | ||
| 2019-03-13 | Thomas John Freeburg | Chief Accounting Officer | Buy | 2,000.00 | 2,000.00 | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000149/0001192482-19-000149-index.htm | ||
| 2020-02-01 | Christina Lampe-Onnerud | Director | Buy | 2,391.00 | 2,391.00 | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000099/0001192482-20-000099-index.htm | ||
| 2020-02-01 | Pablo Marcet | Director | Buy | 2,391.00 | 2,391.00 | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000097/0001192482-20-000097-index.htm | ||
| 2018-03-07 | STEPHEN J SULLIVAN | Director | Buy | 4,800.00 | 24,583.00 | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003195/0001493152-18-003195-index.htm | ||
| 2020-03-12 | JACK E STOVER | President and CEO | Buy | 7,188.00 | 30,271.00 | https://www.sec.gov/Archives/edgar/data/1054102/000149315220005921/0001493152-20-005921-index.htm | ||
| 2018-03-07 | Gregory Richard | Chief Commerical Officer | Buy | 28,000.00 | 31,241.00 | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003187/0001493152-18-003187-index.htm | ||
| 2018-12-05 | JACK E STOVER | President and CEO | Buy | 60,000.00 | 313,378.00 | https://www.sec.gov/Archives/edgar/data/1054102/000119248218000490/0001192482-18-000490-index.htm | ||
| 2018-02-26 | Gregory Richard | Chief Commerical Officer | Buy | 2,000.00 | 3,241.00 | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003187/0001493152-18-003187-index.htm | ||
| 2019-03-13 | JACK E STOVER | President and CEO | Buy | 86,922.00 | 427,300.00 | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000148/0001192482-19-000148-index.htm | ||
| 2019-03-13 | James Early | Chief Financial Officer | Buy | 26,340.00 | 43,340.00 | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000146/0001192482-19-000146-index.htm | ||
| 2018-03-07 | Felice Schnoll-Sussman | Director | Buy | 4,800.00 | 4,800.00 | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003190/0001493152-18-003190-index.htm | ||
| 2020-01-29 | Robert J. Gorman | Director | Buy | 6,321.00 | 7.91 | 49,999.11 | 6,321.00 | https://www.sec.gov/Archives/edgar/data/1054102/000119248220000076/0001192482-20-000076-index.htm |
| 2020-07-29 | James Early | Insider | Buy | 5,000.00 | 7,125.00 | https://www.sec.gov/Archives/edgar/data/1054102/000149315220014326/0001493152-20-014326-index.htm | ||
| 2018-03-07 | JACK E STOVER | President and CEO | Buy | 56,000.00 | 75,738.00 | https://www.sec.gov/Archives/edgar/data/1054102/000149315218003194/0001493152-18-003194-index.htm | ||
| 2019-03-13 | Gregory Richard | Chief Commerical Officer | Buy | 39,528.00 | 84,169.00 | https://www.sec.gov/Archives/edgar/data/1054102/000119248219000147/0001192482-19-000147-index.htm |